Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the continent’s health agenda. Lenias Hwenda maps out why 2026 is a turning point for African patient safety — anchored by the operationalisation of the African Medicines Agency, the launch of the AfriVigilance pharmacovigilance platform, and the first Africa Patient Safety Summit — and makes the case that connecting these pillars is now the continent’s real challenge.
The future of healthcare in Africa will not be defined solely by how many medicines the continent produces or how quickly new therapies become available. It will be defined by something even more fundamental: whether every medicine can be trusted to be safe throughout its entire lifecycle.
For decades, Africa’s health agenda has rightly focused on expanding access to medicines. Today, a new imperative is emerging. Access without safety is not enough. As pharmaceutical manufacturing grows, clinical research expands and regulatory systems mature, ensuring medicines remain safe in real-world use has become one of the continent’s most important strategic priorities.
That is why 2026 represents more than another milestone in African healthcare. It marks the beginning of a new era for patient safety. For the first time, Africa possesses the building blocks of a truly continental medicines safety ecosystem.
The operationalisation of the African Medicines Agency (AMA) establishes the regulatory foundation for greater collaboration, harmonisation and oversight across Member States. At the same time, the launch of AfriVigilance introduces Africa’s first end-to-end digital pharmacovigilance platform, enabling the continent to collect, analyse and share real-world medicines safety data across the entire lifecycle of medical products.
Together, these developments fundamentally change the conversation.
Historically, medicines safety has often been reactive, fragmented and nationally driven. Safety data remained dispersed across institutions, limiting the ability to identify emerging risks or coordinate regulatory responses. AfriVigilance changes that equation by creating continental safety intelligence—transforming individual reports into actionable evidence that can strengthen regulatory decisions, improve clinical practice and enhance public confidence in medicines. But data alone does not save lives.
The real value of safety intelligence lies in how it is translated into action. Regulatory decisions must inform clinical practice. Safety signals must strengthen prescribing behaviours. Healthcare professionals must be equipped to report adverse events. Patients must be empowered to participate in their own safety. Every link in the medicines value chain must work together to prevent avoidable harm.
This is where leadership becomes essential. Patient safety is not the responsibility of regulators alone. It requires alignment between governments, healthcare providers, pharmaceutical manufacturers, researchers, technology innovators and patients themselves. No single institution can build a safer medicines ecosystem in isolation.
The opportunity before Africa is therefore not simply to strengthen pharmacovigilance. It is to reimagine how medicines safety is governed across the continent. This is precisely why the Africa Patient Safety Summit 2026 matters. Rather than another healthcare conference, the Summit represents the first continental platform designed to connect Africa’s emerging medicines safety architecture around a common patient-centred agenda. It is where regulation meets implementation, where pharmacovigilance meets healthcare delivery, and where innovation is translated into measurable improvements in patient outcomes.
The relationship between these three pillars is both distinct and deeply interconnected. AMA provides the regulatory foundation. AfriVigilance provides the safety intelligence. The Africa Patient Safety Summit provides the platform to transform both into coordinated action that protects patients.
This systems-based approach reflects a broader shift taking place across Africa. The continent is no longer simply building stronger institutions. It is creating integrated ecosystems capable of anticipating risk, responding faster and continuously improving the safety of medicines in everyday clinical practice.
For business leaders, policymakers and healthcare innovators alike, this represents an important lesson. Sustainable health systems are built not only on innovation, but on trust. Every adverse drug reaction detected early, every counterfeit or substandard medicine prevented from reaching patients and every regulatory decision informed by real-world evidence strengthens confidence in the healthcare system as a whole. Ultimately, patient safety is a measure of institutional maturity. It reflects whether health systems are capable of learning, adapting and protecting the people they serve.
Africa now has a historic opportunity to build medicines safety into the very architecture of its health systems and not an afterthought. The foundations are in place. The technology is emerging. The regulatory institutions are taking shape.
The challenge for 2026 is no longer building these capabilities. It is connecting them.
If Africa succeeds, 2026 will be remembered not simply as the year new institutions were launched, but as the moment the continent redefined patient safety—from a regulatory obligation to a shared continental commitment that ensures every medicine is not only available and of assured quality, but continuously monitored, safely used and trusted by every patient it is intended to serve.
